Intravesical Reovirus and Anti-PD-1 Combo for Bladder Cancer

What is it about?

This study explores the use of intravesical therapy with an oncolytic reovirus and an anti-PD-1 antibody in treating non-muscle-invasive bladder cancer refractory to intravesical bacillus Calmette-Guérin. The study shows that both monotherapy and combination therapy with reovirus and anti-PD-1 have superior survival compared to controls. The survival advantage is attributed to the immune-responsive tumor microenvironment generated by the combination treatment, which enriches monocytes and decreases myeloid-derived suppressor cells. The research provides a preclinical basis for the use of reovirus in treating NMIBC via an intravesical route and lays the foundation for a phase I trial investigating the combination of intravesical anti-PD-1 antibody and reovirus in humans as a treatment for NMIBC.

Featured Image

Why is it important?

This research is important because it presents a novel preclinical basis for the use of oncolytic reovirus in the treatment of non-muscle-invasive bladder cancer (NMIBC) via an intravesical route. The study showed that the combination of an anti-PD-1 inhibitor and an oncolytic reovirus had a greater effect than either treatment alone, demonstrating potential for improved treatment outcomes for patients with refractory NMIBC. Key Takeaways: 1. Intravesical therapy with a combination of oncolytic reovirus and anti-PD-1 antibody is both feasible and effective, demonstrating improved survival compared to controls. 2. The combination of anti-PD-1 and reovirus treatment led to a tumor-immune profile similar to that of anti-PD-1 treatment alone, suggesting treatment synergy from direct viral oncolysis. 3. The development of human intravesical oncolytic reovirus instillation represents a scalable and novel therapeutic approach for the management of NMIBC, potentially leading to a new treatment option for patients with recurrent/refractory NMIBC after intravesical BCG.